Discover new treatments currently being developed for pancreatic cancer, which has historically been extremely difficult to ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12% of men diagnosed with pancreatic cancer are alive five ...

Adding pamrevlumab to standard chemotherapy did not improve survival in patients with locally advanced pancreatic cancer ...

Pancreatic Cancer Action Network Calls for Urgently Needed Research and Funding for Effective Early Detection Strategy and ...

A phase 2a trial of IMM-1-104 plus chemotherapy demonstrated efficacy and tolerability in first- and second-line pancreatic ...

Today the American Cancer Society called out the need for more progress on pancreatic cancer, citing it as the third-leading ...

Pancreatic cancer is one of the deadliest of all cancers. Only 12 per cent of men diagnosed with pancreatic cancer are alive five years after diagnosis; for women it is 14 per cent.

The aging population and lifestyle-related factors contribute to a surge in pancreatic cancer cases. The aggressive nature of the disease and its high mortality rate demand innovative therapies.

SAN FRANCISCO -- Older patients' survival in metastatic pancreatic cancer had a significant association with baseline ...

Alexander I. Spira, MD, PhD, FACP, discusses the clinical implications of ctDNA for treatment decisions and monitoring in ...

Silexion Therapeutics' SIL-204 exhibits synergy with key pancreatic cancer drugs in preclinical studies. Phase 2/3 trials ...